Childhood Chronic Idiopathic Uveitis in a Multicentre International Cohort.

Children idiopathic measures of outcome uveitis

Journal

Ocular immunology and inflammation
ISSN: 1744-5078
Titre abrégé: Ocul Immunol Inflamm
Pays: England
ID NLM: 9312169

Informations de publication

Date de publication:
21 Feb 2023
Historique:
entrez: 21 2 2023
pubmed: 22 2 2023
medline: 22 2 2023
Statut: aheadofprint

Résumé

Idiopathic uveitis makes up around 50% of non-infectious uveitis but the clinical characteristics in children are poorly understood. To report the demographic, clinical characteristics, and outcomes of children with idiopathic non-infectious uveitis (iNIU) in a multicentric retrospective study. There were 126 (61 female) children with iNIU. The median age at diagnosis was 9.3 years (3-16 years) . Uveitis was bilateral in 106 patients and anterior in 68.At onset,impaired visual acuity and blindness in the worse eye were reported, in 24.4% and 15.1% patients but at 3 years of follow-up, there was a significant improvement in visual acuity (mean 0.11 SD ±0.50 vs 0.42 SD ± 0.59 p < .001). There is a high rate of visual impairment at presentation in children with idiopathic uveitis. The majority of patients have a significant improvement in vision, but 1 in 6 had impaired vision or blindness in their worse eye at 3 years. This is a large retrospective study of children with chronic idiopathic uveitis,There is a high rate of visual impairment at presentation in children with idiopathic uveitis. Although visual acuity improves during follow-up, one in six still had impaired vision or blindness in their worse eye at 3 years.At 3 years, more than half of patients were on immunosuppression and one-third were on a biologic agent.

Autres résumés

Type: plain-language-summary (eng)
This is a large retrospective study of children with chronic idiopathic uveitis,There is a high rate of visual impairment at presentation in children with idiopathic uveitis. Although visual acuity improves during follow-up, one in six still had impaired vision or blindness in their worse eye at 3 years.At 3 years, more than half of patients were on immunosuppression and one-third were on a biologic agent.

Identifiants

pubmed: 36802984
doi: 10.1080/09273948.2023.2169715
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-10

Subventions

Organisme : Medical Research Council
ID : MR/R013926/1
Pays : United Kingdom

Auteurs

Ilaria Maccora (I)

Rheumatology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
NeuroFARBA department, University of Florence, Florence, Italy.

Catherine Guly (C)

Ophthalmology Unit, Bristol Eye Hospital, Bristol, UK.

Cinzia de Libero (C)

Pediatric Ophthalmology Unit, Meyer Children University Hospital, Florence, Italy.

Roberto Caputo (R)

Pediatric Ophthalmology Unit, Meyer Children University Hospital, Florence, Italy.

Athimalaipet V Ramanan (AV)

Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK.
Translational Health Sciences, University of Bristol, Bristol, UK.

Gabriele Simonini (G)

Rheumatology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
NeuroFARBA department, University of Florence, Florence, Italy.

Classifications MeSH